
Vir Biotechnology (VIR) Stock Forecast & Price Target
Vir Biotechnology (VIR) Analyst Ratings
Bulls say
Vir Biotechnology is supported by a highly derisked HDV franchise, as ECLIPSE 1 met both the Week 48 composite endpoint and the key virologic endpoint, with 44.1% achieving TND plus ALT normalization and 79.2% reaching TND, while safety remained clean with no SAEs or discontinuations. The depth of suppression, plus encouraging finite-therapy data from SOLSTICE showing all 10 selected patients maintained SVR12 after stopping treatment, strengthens the case for a differentiated, potentially best-in-disease regimen and supports the planned mid-2027 FDA submission. Beyond HDV, the company has multiple catalysts in oncology, including VIR-5500 advancing to pivotal Ph3 trials in 2027 and partnered programs that could expand the commercial opportunity, while current revenue is still mainly from licensing rights and grants.
Bears say
Vir Biotechnology is exposed to substantial development, regulatory, and manufacturing risk, and its clinical-stage pipeline may fail to demonstrate safety and efficacy in trials, which is especially concerning for programs like tobevibart + elebsiran and VIR-5818. The company also faces intense competition in HDV and TCE therapeutics, while its reliance on license rights and grants suggests limited operating durability and a likely need to raise additional capital to fund long, expensive development timelines. Added pressure comes from FDA change requests that delayed VIR-5818 data release, underscoring execution risk, and from uncertain intellectual property protection that could weaken commercialization prospects.
This aggregate rating is based on analysts' research of Vir Biotechnology and is not a guaranteed prediction by Public.com or investment advice.
Vir Biotechnology (VIR) Analyst Forecast & Price Prediction
Start investing in Vir Biotechnology (VIR)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Vir Biotechnology (VIR) Forecast
Vir Biotechnology (VIR) Analyst Forecast & Price Prediction
Start investing in Vir Biotechnology (VIR)
Order type
Buy in
Order amount
Est. shares
0 shares